Salix, Mitsubishi Tanabe Pharma to Develop and Commercialize MT-1303 for IBD

Salix, Mitsubishi Tanabe Pharma to Develop and Commercialize MT-1303 for IBD
Mitsubishi Tanabe Pharma  and Salix Pharmaceuticals have entered into an exclusive licensing agreement for MT-1303 (amiselimod), a therapeutic agent for autoimmune diseases including inflammatory bowel disease (IBD) and ulcerative colitis. Salix’s shares are all owned by Bausch Health Companies. MT-1303 (amiselimod) is a selective sphingosine 1-phosphate (S1P) receptor antagonist. S1P receptors are proteins expressed on the surface of lymphocytes, a type of immune cell. The oral therapy prevents lymphocytes from exiting the lymph nodes and traveling to other tissues, thus controlling the exacerbated autoimmune response and reducing inflammation. Bausch now has exclusive rights to develop and commercialize MT-1303 around the world, except for Japan and other Asian countries. Mitsubishi will continue to develop the therapy for neurological, rheumatological and certain rare dermatological indications, but MT-1303’s development for any other field is the responsibility of Bausch. According to the licensing agreement, Mitsubishi will receive a one-time upfront payment, development- and regulatory-based milestone payments and sales-based royalties from Bausch. Inflammatory bowel diseases (IBD), which include ulcerative colitis and Crohn's disease, are chronic, disabling, and progressive disorders that require lifelong treatment. Treatment options for IBD aim to stop inflammation and include non-biological therapies, such as steroids, and biological ones, such as anti-tumor necrosis factor (TNF) agents. Using the latter has improved patients’ qualit
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *